Skip to main content
. 2020 May 7;10:44. doi: 10.1186/s13550-020-00633-1

Table 2.

SUVmax and T/N ratio of gliomas

Characteristic MET FLT
SUVmax, median (IQR) T/N ratio, median (IQR) SUVmax, median (IQR) T/N ratio, median (IQR)
Grade
 II (n = 12) 2.99 (1.94–4.23) 2.51 (1.86–3.13) 0.49 (0.30–0.69) 2.24 (1.69–2.62)
 III (n = 24) 5.92 (4.65–6.52) 5.03 (3.58–6.39) 1.29 (0.90–1.49) 6.25 (4.59–8.69)
 IV (n = 45) 6.21 (4.45–7.66) 5.99 (4.64–7.39) 2.77 (1.92–3.29) 15.24 (11.11–20.49)
IDH status
 Mutant (n = 29) 4.83 (3.04–6.37) 3.6 (2.87–5.59) 0.93 (0.47–1.44) 4.18 (2.28–6.39)
 Wildtype (n = 52) 6.11 (4.63–7.56) 5.91 (4.54–7.35) 2.59 (1.61–3.24) 14.7 (8.98–20.39)
Histology and subtype
 DA (n = 9) 2.77 (1.86–3.69) 2.03 (1.83–2.97) 0.46 (0.23–0.57) 2.35 (1.69–2.60)
  IDH-mut (n = 8) 2.76 (1.75–4.01) 2.45 (1.85–3.26) 0.45 (0.23–0.59) 2.07 (1.69–2.62)
  IDH-wt (n = 1) 2.85 1.83 0.57 2.48
 OD (n = 3) 3.68 (3.31–4.29) 2.86 (2.51–3.23) 0.59 (0.49–0.73) 2.14 (1.91–3.42)
 AA (n = 14) 5.22 (4.06–5.84) 4.65 (3.25–5.99) 1.37 (0.89–1.47) 7.16 (4.77–9.41)
  IDH-mut (n = 6) 4.50 (3.14–5.67) 3.28 (2.99–5.19) 0.99 (0.68–1.35) 4.9 (3.48–6.98)
  IDH-wt (n = 8) 5.76 (5.26–5.83) 5.41 (4.11–6.20) 1.66 (0.90–2.36) 8.1 (6.58–14.53)
 AO (n = 10) 6.91 (5.14–7.79) 5.07 (4.72–7.21) 1.18 (0.97–1.49) 5.82 (4.26–6.79)
 GBM (n = 45) 6.21 (4.45–7.66) 5.99 (4.64–7.39) 2.77 (1.92–3.29) 15.24 (11.11–20.46)
  IDH-mut (n = 2) 5.44 (4.64–6.24) 5.6 (5.59–5.60) 1.90 (1.74–2.06) 14.58 (14.47–14.69)
  IDH-wt (n = 43) 6.25 (4.58–7.71) 6.19 (4.63–7.41) 2.81 (1.95–3.32) 15.65 (10.35–20.77)